Skip to main content
. 2017 Mar 28;24(1):35–48. doi: 10.1007/s10989-017-9590-8

Fig. 5.

Fig. 5

a Compound (4) [Abu-Leu-NMe-D-Leu-NMe-Leu- Leu-D-Pro] H.P.V study and control jugular vein study, b Compound (5) [Ala-Leu-NMe-D-Leu-NMe-Leu-Leu-D-Pro] H.P.V study and control jugular vein study (the 24 h point for control jugular vein was below the LLOQ)